Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Resverlogix Corp (RVX.TO)

Resverlogix Corp (RVX.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 210,716
  • Shares Outstanding, K 209,154
  • Annual Sales, $ 0 K
  • Annual Income, $ -162,798 K
  • 60-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 3.96
  • Earnings Per Share ttm 0.18
  • Most Recent Earnings 0.02 on 01/31/20
  • Next Earnings Date 03/20/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.79 +15.19%
on 03/16/20
1.30 -30.00%
on 03/10/20
-0.28 (-23.53%)
since 03/09/20
3-Month
0.79 +15.19%
on 03/16/20
1.53 -40.52%
on 02/03/20
-0.26 (-22.22%)
since 01/09/20
52-Week
0.35 +160.00%
on 09/30/19
4.94 -81.58%
on 05/08/19
-2.42 (-72.67%)
since 04/09/19

Most Recent Stories

More News
Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication

Epigenetic BET-inhibition to combat COVID-19

RVXCF : 0.6690 (-5.41%)
RVX.TO : 0.91 (-9.00%)
Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research

Recent findings point to BET protein and ACE2 inhibition as possible means to slow and reduce the impact of COVID-19

RVXCF : 0.6690 (-5.41%)
RVX.TO : 0.91 (-9.00%)
Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce the U.S. Food & Drug Administration ("FDA") has granted Breakthrough Therapy Designation for apabetalone in combination...

RVXCF : 0.6690 (-5.41%)
RVX.TO : 0.91 (-9.00%)
CORRECTION: Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD

In a release issued earlier today under the same headline by Resverlogix Corp. (TSX: RVX), please note that the subheadline should read "BETonMACE Results Show 57% Hazard Reduction in Primary MACE for...

RVXCF : 0.6690 (-5.41%)
RVX.TO : 0.91 (-9.00%)
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce today additional highly significant findings and clear synergy when apabetalone is combined with anti-diabetic therapies,...

RVXCF : 0.6690 (-5.41%)
RVX.TO : 0.91 (-9.00%)
Resverlogix Appoints Dicky To to its Board of Directors

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced that Mr. Dicky To has been appointed to the Company's Board of Directors. His appointment is effective as of December 19, 2019....

RVXCF : 0.6690 (-5.41%)
RVX.TO : 0.91 (-9.00%)
Resverlogix Announces Change to its Board of Directors

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced that Dr. Eldon Smith has stepped down from the Board of Directors, effective today.

RVXCF : 0.6690 (-5.41%)
RVX.TO : 0.91 (-9.00%)
Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) reminds stakeholders that the Company will hold a conference call and webcast on December 6 at 8:30 am ET to supplement the presentation of...

RVXCF : 0.6690 (-5.41%)
RVX.TO : 0.91 (-9.00%)
Resverlogix Announces Warrant Exercise Incentive Program

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announces a warrant exercise incentive program ("Incentive Program") designed to encourage the early exercise of 15,593,428 warrants to purchase...

RVXCF : 0.6690 (-5.41%)
RVX.TO : 0.91 (-9.00%)
Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that it has scheduled a conference call and webcast to supplement the presentation of BETonMACE results to be made during the...

RVXCF : 0.6690 (-5.41%)
RVX.TO : 0.91 (-9.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 1.10
1st Resistance Point 1.01
Last Price 0.91
1st Support Level 0.86
2nd Support Level 0.80

See More

52-Week High 4.94
Fibonacci 61.8% 3.19
Fibonacci 50% 2.64
Fibonacci 38.2% 2.10
Last Price 0.91
52-Week Low 0.35

See More

Business Summary

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases....

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar